Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | The molecular complexity of CML

Jerald P. Radich • 23 Aug 2020
SOHO 2020
Chronic Myeloid Leukemia Leukemia

Jerald P. Radich, MD, University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, outlines the molecular complexity of chronic myeloid leukemia (CML) as well as the heterogeneity of the disease, and how this can inform treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jerald P. Radich

3:59
ENESTnd: results from an exploratory biomarker analysis in CML
Jerald P. Radich • 24 Aug 2020
4:27
CML management in resource limited countries
Jerald P. Radich • 23 Aug 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals